MedTrace Logo

A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers

NCT06086613 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2025-01-10

No results posted yet for this study

Summary

To understand if AGA2115 is safe and well tolerated in healthy adult volunteers.

Conditions

Interventions

DRUG

AGA2115

In Part A, participants will receive AGA2115 as a single dose administered as a subcutaneous (SC) injection (5 cohorts) or as an intravenous (IV) infusion (1 cohort). In Part B, participants will receive AGA2115 in multiple doses administered as a SC injection.

DRUG

Placebo

In Part A, participants will receive single dose of placebo administered as a SC injection (5 cohorts) or IV infusion (1 cohort). In Part B, participants will receive multiple doses of placebo administered as a SC injection.

Sponsors & Collaborators

  • Angitia Incorporated Limited

    lead INDUSTRY

Principal Investigators

  • Angitia Medical Director · Angitia Incorporated Limited

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-03
Primary Completion
2024-10-17
Completion
2024-10-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06086613 on ClinicalTrials.gov